Table 2.
Baseline characteristics of the study group based on 8312 non-TNBC patients and 844 TNBC patients included in the study
| |
Non-TNBC |
TNBC |
|
|||
|---|---|---|---|---|---|---|
| |
8312 (90.8%) |
844 (9.2%) |
|
|||
| Mean | N | Mean | N | p-value | ||
|
Age (range) |
61.2 (22; 97) |
8312 |
57.7 (27; 97) |
844 |
<0.001 |
|
|
Postmenopausal |
74.8% |
6220 |
66% |
557 |
<0.001 |
|
|
T 1 |
55.3% |
4600 |
48.5% |
409 |
<0.001 |
|
|
T 2 |
36% |
2995 |
41.4% |
349 |
|
|
|
T 3 |
3.8% |
313 |
5.9% |
50 |
|
|
|
T4 |
4.9% |
404 |
4.3% |
36 |
|
|
|
Node negative |
59.9% |
4979 |
62.6% |
528 |
0.133 |
|
|
1-3 |
23.8% |
1978 |
20% |
169 |
|
|
|
>3 |
16.3% |
1355 |
17.4% |
147 |
|
|
|
G 1 |
9.9% |
820 |
1.4% |
12 |
<0.001 |
|
|
G 2 |
65.5% |
5447 |
25.4% |
214 |
|
|
|
G 3 |
24.6% |
2045 |
73.2% |
618 |
||
|
ASA Score >3 |
21.7% |
1068 |
18.3% |
94 |
0.072 |
|
|
NYHA Class > III |
3.5% |
92 |
4.0% |
12 |
0.652 |
|
|
Myocardial infarction, stroke, or TIA |
4.2% |
230 |
3.4% |
19 |
0.340 |
|
|
HR negative |
5.8% |
481 |
100.0% |
844 |
<0.001 |
|
|
HR IRS 1-5 |
23.5% |
1953 |
0.0% |
0 |
|
|
|
HR positive |
70.7% |
5878 |
0.0% |
0 |
|
|
|
Her2neu positive |
17.7% |
1468 |
0.0% |
0 |
<0.001 |
|
|
Endocrine therapy |
82.0% |
6816 |
5.6% |
47 |
<0.001 |
|
|
Chemotherapy |
43.0% |
3575 |
77.1% |
651 |
<0.001 |
|
|
Mastectomy |
29.0% |
2414 |
26.7% |
225 |
0.145 |
|
| Radiotherapy | 79.2% | 6579 | 80.3% | 678 | 0.420 | |
ASA, NYHA, and myocardial infarction/stroke/TIA were available for 4911, 2608, and 5466 non-TNBC patients and for 513, 297, and 564 TNBC-patients, respectively.